Companies › Atamyo Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATA-100 AAV9 gene therapy delivering FKRP gene | FKRP | Phase 1 | LGMDR9 | Sep 2029 |
| ATA-200 SGCG gene replacement therapy | SGCG | Phase 1 | LGMD2C | Jan 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05224505 | ATA-100 | Phase 1 | LGMDR9 | Neurology | Sep 2029 |
| NCT05973630 | ATA-200 | Phase 1 | LGMD2C | Neurology | Jan 2031 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.